Could this be the catalyst for share price increase and then fa...

Could this be the catalyst for share price increase and then fa capital raise following? LMAO

Rhythm Biosciences launches Shareholder Benefits Program

We're pleased to announce the launch of our new Shareholder Benefits Program, designed to give back to our investor community in a meaningful and health-focused way.

The program will initially provide shareholders access to our internationally recognised geneType™ multi-test, supporting personalised risk assessment for serious diseases including:

Breast, Colorectal, Melanoma, Pancreatic, Ovarian & Prostate Cancer

geneType™ is a simple saliva-based test that combines genetic, clinical, and family history data to provide comprehensive, personalised risk insights — helping individuals take proactive steps towards better health.

Looking ahead, we also intend to expand the program to include ColoSTAT®, our innovative blood-based colorectal cancer test, pending final regulatory approvals.

"...this program provides an added benefit to ownership and aims to keep our shareholders healthy," said Rhythm CEO, Dr David Atkins.